OPC Pharmaceutical JSC (HOSE:OPC)
Vietnam · Delayed Price · Currency is VND 20,800
0.00 (0.00%)
At close: Aug 27, 2026
OPC Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,153,676 | 1,122,987 | 968,576 | 1,004,887 | 1,171,614 | 1,123,728 | |
Revenue Growth | 17.84% | 15.94% | -3.61% | -14.23% | 4.26% | 16.38% |
Cost of Revenue | 627,777 | 591,453 | 522,458 | 526,456 | 637,906 | 643,499 |
Gross Profit | 525,900 | 531,534 | 446,118 | 478,431 | 533,708 | 480,229 |
Selling, General & Admin | 391,358 | 399,245 | 311,684 | 332,311 | 355,073 | 313,516 |
Operating Expenses | 391,358 | 399,245 | 311,684 | 332,311 | 355,073 | 313,516 |
Operating Income | 134,542 | 132,289 | 134,434 | 146,120 | 178,636 | 166,713 |
Interest Expense | - | - | - | -334.55 | -925.2 | -4,819 |
Interest & Investment Income | 11,771 | 11,916 | 8,335 | 15,854 | 7,813 | 3,707 |
Earnings From Equity Investments | 2,203 | 1,932 | 1,535 | 838.45 | 797.74 | 172.88 |
Currency Exchange Gain (Loss) | 397.9 | 861.55 | 448.73 | 555.41 | 279.37 | 360.84 |
Other Non Operating Income (Expenses) | -4,572 | -6,114 | -7,627 | -7,710 | -6,677 | -6,894 |
EBT Excluding Unusual Items | 144,341 | 140,885 | 137,126 | 155,323 | 179,924 | 159,241 |
Gain (Loss) on Sale of Investments | 7,159 | 7,159 | - | - | - | - |
Pretax Income | 151,500 | 148,043 | 137,126 | 155,323 | 179,924 | 159,241 |
Income Tax Expense | 32,744 | 31,623 | 27,672 | 33,004 | 37,530 | 35,878 |
Earnings From Continuing Operations | 118,756 | 116,420 | 109,454 | 122,319 | 142,394 | 123,363 |
Minority Interest in Earnings | 173.96 | -539.6 | -2,394 | -84.74 | -266.22 | 3,014 |
Net Income | 118,930 | 115,881 | 107,060 | 122,234 | 142,128 | 126,377 |
Preferred Dividends & Other Adjustments | 17,748 | 17,382 | 12,652 | 18,677 | 14,010 | 13,416 |
Net Income to Common | 101,182 | 98,499 | 94,408 | 103,557 | 128,118 | 112,961 |
Net Income Growth | 12.36% | 4.33% | -8.83% | -19.17% | 13.42% | 19.16% |
Shares Outstanding (Basic) | 75 | 75 | 75 | 75 | 75 | 75 |
Shares Outstanding (Diluted) | 75 | 75 | 75 | 75 | 75 | 75 |
Shares Change | - | - | - | - | - | -0.00% |
EPS (Basic) | 1350.18 | 1314.37 | 1259.79 | 1381.88 | 1709.61 | 1507.36 |
EPS (Diluted) | 1350.18 | 1314.37 | 1259.79 | 1381.88 | 1709.40 | 1507.36 |
EPS Growth | 12.36% | 4.33% | -8.83% | -19.16% | 13.40% | 19.16% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 27,238 | 41,675 | 12,147 | 243,317 | 28,688 | 181,809 |
Free Cash Flow Per Share | 363.46 | 556.12 | 162.09 | 3246.84 | 382.82 | 2426.08 |
Dividend Per Share | 683.761 | 683.761 | - | 1282.051 | 1282.051 | - |
Dividend Growth | - | - | - | 0% | 20.50% | - |
Gross Margin | 45.59% | 47.33% | 46.06% | 47.61% | 45.55% | 42.73% |
Operating Margin | 11.66% | 11.78% | 13.88% | 14.54% | 15.25% | 14.84% |
Profit Margin | 8.77% | 8.77% | 9.75% | 10.30% | 10.94% | 10.05% |
Free Cash Flow Margin | 2.36% | 3.71% | 1.25% | 24.21% | 2.45% | 16.18% |
EBITDA | 155,922 | 153,844 | 156,735 | 169,015 | 201,454 | 189,215 |
EBITDA Margin | 13.51% | 13.70% | 16.18% | 16.82% | 17.20% | 16.84% |
D&A For EBITDA | 21,381 | 21,555 | 22,301 | 22,895 | 22,819 | 22,502 |
EBIT | 134,542 | 132,289 | 134,434 | 146,120 | 178,636 | 166,713 |
EBIT Margin | 11.66% | 11.78% | 13.88% | 14.54% | 15.25% | 14.84% |
Effective Tax Rate | 21.61% | 21.36% | 20.18% | 21.25% | 20.86% | 22.53% |
Revenue as Reported | 1,153,676 | 1,122,987 | 968,576 | 1,004,887 | 1,171,614 | 1,123,728 |
Advertising Expenses | - | 66,590 | 43,302 | 51,343 | 48,858 | 40,148 |